Apolipoprotein A1 (Apo A1) is a useful biomarker of tumor burden and prognostic factor of multiple myeloma (MM), according to a study published in the Chinese Journal of Hematology.
In this study, researchers evaluated 412 patients with MM. They analyzed data using SPSS 22.0, T-test, Mann-Whitney U-test or one-way analysis of variance, and Spearman rank correlation coefficients. The
receiver operating characteristic curve was used to calculate the cutoff value and compared the overall survival (OS) and progression-free survival (PFS) between high Apo A1 subgroup and low Apo A1 subgroup with Kaplan-Meier survival analysis.
According to the results, the value of Apo A1 in the patient group was lower than that in the control group (0.89 g/L vs. 1.24 g/L; P<0.05). The researchers observed Apo A1 increased when MM was in remission and decreased following disease progression. A multivariate analysis showed Apo A1 reduction had become one of the independent risk factors of MM.
The researchers concluded, “On the basis of Kaplan-Meier survival analysis between high Apo A1 subgroup and low Apo A1 subgroup, we found higher Apo A1 patients had longer OS rate and PFS. Apo A1 is a useful biomarker of tumor burden and a prognostic factor of MM.”